Drug Target Review – Issue 4 2023

As we navigate the current landscape of pharmaceutical exploration, we discern a future in which healthcare is characterised by personalised medicines and precision-targeted treatments. To provide comprehensive insights into ongoing developments, we are pleased to present the latest edition of Drug Target Review. This issue encompasses a spectrum of topics, including proteomics, upstream bioprocessing, immuno-oncology, CRISPR and screening.

Within the pages of this publication, readers will find in-depth articles that elucidate the latest advancements, challenges, and breakthroughs within the field of drug discovery.

Drug Target Review explores the potential of stem cells in personalised regenerative medicine. Jinhyeok Jeong from Samsung Biologics takes us on a journey from cell cultures to drug products, providing insights into the intricacies of bioprocessing.

Dr Sergio Quezada, representing Achilles Therapeutics, highlights the unique nature of neoantigens, while Dr Roy Maute of Pheast Therapeutics explores the potential of CD24 in cancer immunotherapy.

Dr Piotr Trzonkowski, from the University of Gdansk, highlights how TREGs offer hope for personalised medicine in autoimmune diseases. Dr Susanne Rafelski, from the Allen Institute for Cell Science, presents a framework for comprehending cell organisation and variation. Dr Amanda Haupt, from Revvity, discusses the emergence of base editing as a therapeutic tool.

Within this issue, you’ll encounter a diverse collection of insights and innovations that play a pivotal role in shaping the trajectory of drug discovery for the future. Explore new discoveries and developments by leading experts in the field.

Some articles included in this issue:

• IMMUNO-ONCOLOGY
  Not all neoantigens are created equal
  Dr Sergio Quezada, Achilles Therapeutics 
• PERSONALISED MEDICINE 
  TREGs offer personalised medicine hope in autoimmune disease
  Peter Trzonkowski, Medical University of Gdansk 
• SCREENING
  New genetic test to screen for foetal DNA sequence variants
  Ellen Capon, Drug Target Review
• HIT TO LEAD
  Framework for understanding cell organisation and variation
  Dr Susanne Rafelski, Allen Institute  
• CRISPR 
  The emergence of base editing as a therapeutic genome engineering tool 
  Dr Amanda Haupt, Revvity

Exciting news for 2024! 

We will be bidding farewell to the current Drug Target Review magazine and launching a series of innovative offerings for the upcoming year.

• Topic-specific eBooks: Delve into key topics and hear more from our editor and industry leaders
• Editorial webinars: Our editor Taylor Mixides will lead a series of webinars focussed on the latest topics in the industry. Key speakers will share the latest insights and innovations in these one-hour sessions
• Thought leadership podcasts: Gain information and insights on the go with one of our new podcasts! 

Interested in contributing your research? Contact Taylor Mixides for more information.

We look forward to sharing these with you soon, and hope you find the information useful.